Envestnet Portfolio Solutions
CPRX

Envestnet Portfolio Solutions’s Catalyst Pharmaceutical CPRX Stock Holding History

Envestnet Portfolio Solutions’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$691K Buy
21,996
+1,876
+9% +$55.4K ﹤0.01% 853
2026
Q1 		$498K Sell
20,120
-184
-0.9% -$4.38K ﹤0.01% 906
2025
Q4 		$474K Sell
20,304
-176
-0.9% -$3.92K ﹤0.01% 1086
2025
Q3 		$403K Sell
20,480
-2,896
-12% -$59.6K ﹤0.01% 1112
2025
Q2 		$507K Buy
23,376
+14,686
+169% +$347K ﹤0.01% 1093
2025
Q1 		$211K Buy
+8,690
New +$196K ﹤0.01% 1482

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Portfolio Solutions's CPRX Position: Q2 2026 in Review

Envestnet Portfolio Solutions increased its Catalyst Pharmaceutical (CPRX) stake by 9.3% in Q2 2026, buying an estimated $55.4K and bringing the position to 21,996 shares worth $691K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Envestnet Portfolio Solutions first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Envestnet Portfolio Solutions held 21,996 shares of Catalyst Pharmaceutical worth $691K as of Q2 2026.
  • Envestnet Portfolio Solutions bought 1,876 Catalyst Pharmaceutical shares in Q2 2026, an estimated $55.4K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q2 2026, its #853 holding.
  • Envestnet Portfolio Solutions first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2026, filed 20 Jul 2026.